Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bojungikki-tang and Pembrolizumab in Advanced Non-small Cell Lung Cancer
NCT06249854Phase 2Completed
- Sponsor
- Korea Institute of Oriental Medicine
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Botanical drug
- Countries
- 1
01
Overview
A Phase 2 trial of Bojungikki-tang in non-small cell lung cancer (NSCLC), sponsored by Korea Institute of Oriental Medicine. Started Feb 2024; status: completed.
02
Drugs
Bojungikki-tang
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06249854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06249854.